Navigation Links
Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
Date:12/16/2008

information, go to www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "seek," "expect," "estimate," "project," "achieve," "show," "demonstrate," "offer," "plan," "may," "will," "extend," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the nature and extent of additional Adlea clinical trials that may be required by the U.S. Food and Drug Administration prior to Anesiva's submission of an application for approval to market Adlea, and whether any such additional trials will be successful. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007, and its most recent filing on Form 10-Q.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the 1600’s ... known as “The Doctor’s Plague.” In this time period, doctors ... This led, at times, to the death of vulnerable patients. ... don’t know that they may be unwittingly transmitting herpes viruses ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... Scientific Corporation (NYSE: BSX ) has ... with left main coronary disease who were treated ... SYNTAX-LE MANS is a substudy of the landmark ...
... ( http://www.gene2drug.com ) -- the ... science industry -- announces the publication of its latest ... for Commercial Suppliers, Vol. III." Given the highly ... report is designed to create opportunities for differentiation by ...
... Cholesterol Test for determining heart disease riskBIRMINGHAM, Ala., May ... developer of the VAP Cholesterol Test, has announced it ... and report apolipoprotein B100 (apoB) using the Vertical Auto ... of the VAP Cholesterol Test to accurately report apoB, ...
Cached Biology Technology:SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5BioInformatics, LLC New Report -- The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III 2Atherotech Receives Patent for ApoB Measurement 2Atherotech Receives Patent for ApoB Measurement 3
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
(Date:7/9/2014)... The Cancer Genome Atlas (TCGA) Research Network have ... in lung adenocarcinoma, the most common subtype of ... expand the number of possible therapeutic targets for ... of patients with treatable mutations because many potent ... , TCGA is jointly funded and managed by ...
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... malaria vaccine development, scientists have used genomics,proteomics and ... on a molecular level as they move between ... complex life cycle is helping researchers,understand when different ... through seven different life stages. In turn, that,molecular-level ...
... seabirds accustomed to nesting on islands free of predators ... islands in the Aleutian archipelago in the 18th century. ... A study published this week in the journal Science ... rippled through entire island ecosystems, transforming the vegetation from ...
... innovation involving the sharing of genes between two ... between them for the,survival of both species populations.,The ... two species can give rise to a system ... - in this case, the production of,worker ants ...
Cached Biology News:Scientists reveal molecular secrets of the malaria parasite 2Scientists reveal molecular secrets of the malaria parasite 3Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 2Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 3Introduced foxes transformed vegetation on Aleutian Islands from lush grasslands to tundra 4Ants Genetic Engineering Leads To Species Interdependency 2
Protein Marker Detection Pack contains biotinylate...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: